Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Adjunctive use of metformin in the treatment of atypical antipsychotic-induced weight gain
Ist Teil von
Medicinski pregled, 2022, Vol.75 (5-6), p.151-157
Erscheinungsjahr
2022
Quelle
EZB Electronic Journals Library
Beschreibungen/Notizen
Introduction. Atypical antipsychotics are the gold standard in the treatment
of psychotic and other mental disorders due to their efficacy and
tolerability. However, the relatively frequent occurrence of
antipsychotic-induced metabolic syndrome has encouraged research into
possible solutions to this problem, including the adjunctive use of
metformin. The aim of this review article is to present a concise,
comprehensive and critical overview of the aforementioned issue based on the
analysis of available experimental research. Material and Methods. PubMed
and Google Scholar databases were searched for relevant literature published
in a fifteen-year period between 2008 and 2022. The following terms were
used in the search: atypical antipsychotics, metformin, and weight gain.
Only double-blind, placebo-controlled, randomized, and cohort studies were
taken into consideration. Results. A total of 145 papers were analyzed, of
which 10 papers with 852 subjects met the inclusion criteria. All the
reviewed studies concluded that the adjunctive administration of metformin
at a daily dose of 500 mg to 2,000 mg has significantly reduced atypical
antipsychotic-induced weight gain, with a favorable effect on other
metabolic parameters that were examined in the analyzed papers. Conclusion.
Taking into account the increased cardiovascular morbidity and the
consequent mortality among those who have been using atypical antipsychotics
in the long term, it is necessary to assess the risks and benefits of
introducing adjunctive metformin in every patient who is at risk of
developing metabolic syndrome. In order to recommend the routine use of
metformin in such indications, studies that would include a larger sample
and a longer period of treatment are needed.